Skip to main content
logo
Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
13.25
+0.28 (2.16%)
Nov 9, 2026, 9:43 AM EST - Market open

Kailera Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Cash & Equivalents
106.54160.27175.18
Short-Term Investments
794.92385.79-
Cash & Short-Term Investments
901.45546.06175.18
Cash Growth
-211.72%-
Other Receivables
6.262.73-
Receivables
6.262.73-
Prepaid Expenses
7.157.522.09
Other Current Assets
4.891.230.34
Total Current Assets
919.76557.54177.61
Property, Plant & Equipment
11.2812.420.68
Long-Term Investments
136.19106.67-
Long-Term Deferred Charges
-2.60.15
Other Long-Term Assets
14.9513.07-
Total Assets
1,082692.29178.45

Liabilities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Accounts Payable
9.437.532.01
Accrued Expenses
30.0536.922.23
Current Portion of Leases
1.091.040.51
Other Current Liabilities
1.550.922.16
Total Current Liabilities
42.1246.416.91
Long-Term Leases
8.889.71-
Other Long-Term Liabilities
0.070.27-
Total Liabilities
51.0656.396.91

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Additional Paid-In Capital
1,68911.980.94
Retained Earnings
-654.51-368.67-219.71
Comprehensive Income & Other
-3.740.23-
Total Common Equity
1,031-356.46-218.77
Shareholders' Equity
1,031635.91171.53
Total Liabilities & Equity
1,082692.29178.45

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Total Debt
9.9710.750.51
Net Cash (Debt)
1,028641.98174.67
Net Cash Growth
-267.54%-
Net Cash Per Share
7.9233703.01-
Filing Date Shares Outstanding
129.850.02-
Total Common Shares Outstanding
129.680.02-
Working Capital
877.64511.13170.7
Book Value Per Share
7.95-18713.67-
Tangible Book Value
1,031-356.46-218.77
Tangible Book Value Per Share
7.95-18713.67-
Machinery
-1.490.26
Leasehold Improvements
-0.56-
SEC Filings: 10-K · 10-Q